51. Scleroderma Clinical trials / Disease details
Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00577304 (ClinicalTrials.gov) | December 2007 | 18/12/2007 | A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon | A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon | Raynaud's Disease;Raynaud's Disease Secondary to Scleroderma;Raynaud's Disease Secondary to Other Autoimmune Disease | Drug: Nitroglycerin;Drug: Topical AmphiMatrix | MediQuest Therapeutics | NULL | Active, not recruiting | 15 Years | 70 Years | Both | 200 | Phase 3 | United States |
| 2 | NCT00419419 (ClinicalTrials.gov) | December 2006 | 4/1/2007 | Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon | Phase III In-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon | Raynaud's Disease;Scleroderma;Autoimmune Diseases | Drug: Topical AmphiMatrix with nitroglycerin (MQX-503) | MediQuest Therapeutics | NULL | Completed | 18 Years | 70 Years | Both | 80 | Phase 3 | United States;Sweden;United Kingdom |